Periodontal regenerative procedures for patients with periodontal disease: a review of clinical effectiveness
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001194
English
Authors' recommendations:
For the treatment of intrabony defects, the majority of evidence showed that the use EMD, GTR, and BGS as adjunctive to periodontal surgery (OFD) yields significant benefit in clinical outcomes measured by CAL gain and PPD reduction. For EMD, the recent systematic review did not find any significant changes in radiographic bone levels compared to OFD despite significant differences in clinical parameters. The findings of three RCTs do not support the use of EMD during routine non-surgical scaling and root planning. For GTR, there was evidence for a significant improvement in bone gain compared to OFD for treatment of intrabony defects. GTR was also found to result in greater improvement in attachment levels for treatment of furcation defects. For BGS, meta-analytic results of a systematic review showed that the application of all bone substitutes, except bioactive lass, in conjunction to OFD, resulted in significant gain in bone fill for the treatment of intrabony defects. The benefit of the combined periodontal regenerative therapy in term of cost and effectiveness remains to be determined. Overall, despite ample evidence showing significant clinical benefit of different periodontal regenerative modalities compared to the conventional OFD, heterogeneity across studies was substantial, the differences between tests and controls were often modest, and both test and control groups showed significant improvement in either clinical or radiographic outcomes at the end of study compared to baseline.
Details
Project Status:
Completed
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Bone Regeneration
- Periodontitis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.